In vivo effects of TGF-β inhibition have also been studied with the TGF-β type I receptor kinase inhibitor SD-208, and shown to increase bone mass in mammary tumor-bearing mice (Mohammad KS, Stebbins E, Kingsley L, et al. J Bone Miner Metab. This evidence concerns the gene TGFB1 and breast cancer.